PureTech Health (LON:PRTC) Trading Up 14.2% - Time to Buy?

Key Points

• PureTech Health's stock experienced a significant rise of 14.2%, closing at GBX 121.50 ($1.64) with a high of GBX 123.80 during trading.
• The company's trading volume surged by 1,053%, with approximately 9 million shares changing hands compared to an average of around 781,000 shares.
• Insider Bharatt Chowrira bought 167,739 shares at an average price of GBX 1 per share, indicating confidence in the company's prospects, with insiders owning 13.13% of the stock.

Shares of PureTech Health plc (LON:PRTC - Get Free Report) rose 14.2% on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 4.2%

The stock has a fifty day moving average of GBX 129.46 and a 200 day moving average of GBX 129.72. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The company has a market capitalization of £303.07 million, a PE ratio of 737.65 and a beta of 1.02.

Insider Buying and Selling

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were bought at an average cost of GBX 1 per share, with a total value of £1,677.39. Corporate insiders own 13.13% of the company's stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.